CoChat
Sign Up
Cited by 12Peripheral Artery Disease ManagementVascular Procedures and ComplicationsAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record, with a small difference in title or year; 10 of the 10 references it cites were found in a registry or an index.

Medical Treatment of Peripheral Artery Disease

Gornik, Heather L., Creager, Mark A.·2013·Vascular Medicine: A Companion to Braunwald's Heart Disease
DOI 10.1016/b978-1-4377-2930-6.00019-7
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-1-4377-2930-6.00019-7

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 10 references

Research works printed but not linked: 224

  1. Hirsch, 2006, Circulation, 113, e463, 10.1161/CIRCULATIONAHA.106.174526 · DOI · Paper page
  2. Rooke, 2011, Circulation, 124, 2020, 10.1161/CIR.0b013e31822e80c3 · DOI
  3. Gardner, 1996, The effect of cigarette smoking on exercise capacity in patients with intermittent claudication, Vasc Med, 1, 181, 10.1177/1358863X9600100302 · DOI
  4. Quick, 1982, The measured effect of stopping smoking on intermittent claudication, Br J Surg, 69, S24, 10.1002/bjs.1800691309 · DOI
  5. Jonason, 1987, Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality, Acta Med Scand, 221, 253, 10.1111/j.0954-6820.1987.tb00891.x · DOI
  6. Powell, 1990, Changing the smoking habit and its influence on the management of vascular disease, Acta Chir Scand Suppl, 555, 99
  7. Faulkner, 1983, The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease, Med J Aust, 1, 217, 10.5694/j.1326-5377.1983.tb99395.x · DOI
  8. Lassila, 1988, Cigarette smoking and the outcome after lower limb arterial surgery, Acta Chir Scand, 154, 635
  9. Law, 1995, An analysis of the effectiveness of interventions intended to help people stop smoking, Arch Intern Med, 155, 1933, 10.1001/archinte.1995.00430180025004 · DOI
  10. Hennrikus, 2010, Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial, J Am Coll Cardiol, 56, 2105, 10.1016/j.jacc.2010.07.031 · DOI
  11. Jorenby, 2006, Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial, JAMA, 296, 56, 10.1001/jama.296.1.56 · DOI · Paper page
  12. Rigotti, 2011, Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial, Circulation, 121, 221, 10.1161/CIRCULATIONAHA.109.869008 · DOI
  13. Bowlin, 1994, Epidemiology of intermittent claudication in middle-aged men, Am J Epidemiol, 140, 418, 10.1093/oxfordjournals.aje.a117264 · DOI
  14. Newman, 1993, Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group, Circulation, 88, 837, 10.1161/01.CIR.88.3.837 · DOI
  15. Murabito, 1997, Intermittent claudication. A risk profile from the Framingham Heart Study, Circulation, 96, 44, 10.1161/01.CIR.96.1.44 · DOI · Paper page
  16. Fowkes, 1992, Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study, Am J Epidemiol, 135, 331, 10.1093/oxfordjournals.aje.a116294 · DOI
  17. Mowat, 1997, Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease, Atherosclerosis, 131, 161, 10.1016/S0021-9150(97)06097-8 · DOI
  18. Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 · DOI · Paper page
  19. 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
  20. Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 · DOI · Paper page
  21. 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 · DOI · Paper page
  22. Zheng, 1997, Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study, Atherosclerosis, 131, 115, 10.1016/S0021-9150(97)06089-9 · DOI
  23. Heart Protection Study Collaborative Group, 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 · DOI · Paper page
  24. Pedersen, 1998, Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S), Am J Cardiol, 81, 333, 10.1016/S0002-9149(97)00904-1 · DOI
  25. 1999, MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience, Eur Heart J, 20, 725, 10.1053/euhj.1998.1350 · DOI
  26. Heart Protection Study Collaborative Group, 2007, Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions, J Vasc Surg, 45, 645, 10.1016/j.jvs.2006.12.054 · DOI
  27. Goldbourt, 1997, Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men, Arterioscler Thromb Vasc Biol, 17, 107, 10.1161/01.ATV.17.1.107 · DOI
  28. Gordon, 1989, High-density lipoprotein–the clinical implications of recent studies, N Engl J Med, 321, 1311, 10.1056/NEJM198911093211907 · DOI · Paper page
  29. 2000, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study, Circulation, 102, 21, 10.1161/01.CIR.102.1.21 · DOI · Paper page
  30. Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 · DOI · Paper page
  31. Psaty, 2003, Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis, JAMA, 289, 2534, 10.1001/jama.289.19.2534 · DOI
  32. 2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981 · DOI · Paper page
  33. Lip, 2003, Treatment of hypertension in peripheral arterial disease, Cochrane Database Syst Rev, 10.1002/14651858.CD003075 · DOI
  34. Frishman, 1988, Beta-adrenergic receptor blockers. Adverse effects and drug interactions, Hypertension, 11, II21, 10.1161/01.HYP.11.3_Pt_2.II21 · DOI
  35. Rodger, 1976, Intermittent claudication complicating beta-blockade, BMJ, 1, 1125, 10.1136/bmj.1.6018.1125 · DOI
  36. Roberts, 1987, Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication, Lancet, 2, 650, 10.1016/S0140-6736(87)92441-X · DOI
  37. Solomon, 1991, Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination, BMJ, 303, 1100, 10.1136/bmj.303.6810.1100 · DOI
  38. 1981, Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction, N Engl J Med, 304, 801, 10.1056/NEJM198104023041401 · DOI
  39. 1982, A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results, JAMA, 247, 1707, 10.1001/jama.1982.03320370021023 · DOI
  40. Mangano, 1996, Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group, N Engl J Med, 335, 1713, 10.1056/NEJM199612053352301 · DOI
  41. Poldermans, 1999, The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group, N Engl J Med, 341, 1789, 10.1056/NEJM199912093412402 · DOI
  42. Radack, 1991, Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials, Arch Intern Med, 151, 1769, 10.1001/archinte.1991.00400090063012 · DOI
  43. Espinola-Klein, 2011, Beta-blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial, Hypertension, 58, 148, 10.1161/HYPERTENSIONAHA.110.169169 · DOI
  44. Diehm, 2011, Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication, J Hypertens, 29, 1448, 10.1097/HJH.0b013e3283471151 · DOI
  45. Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 · DOI · Paper page
  46. Overlack, 1994, ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group, Am J Med, 97, 126, 10.1016/0002-9343(94)90022-1 · DOI
  47. Ahimastos, 2006, Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial, Ann Intern Med, 144, 660, 10.7326/0003-4819-144-9-200605020-00009 · DOI
  48. Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension, N Engl J Med, 338, 645, 10.1056/NEJM199803053381003 · DOI
  49. Mehler, 2003, Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes, Circulation, 107, 753, 10.1161/01.CIR.0000049640.46039.52 · DOI
  50. 1996, The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE Study Investigators, Can J Cardiol, 12, 127
  51. Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317 · DOI · Paper page
  52. Adler, 2002, UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes, Diabetes Care, 25, 894, 10.2337/diacare.25.5.894 · DOI · Paper page
  53. Meijer, 1998, Peripheral arterial disease in the elderly: the Rotterdam Study, Arterioscler Thromb Vasc Biol, 18, 185, 10.1161/01.ATV.18.2.185 · DOI
  54. Jude, 2001, Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome, Diabetes Care, 24, 1433, 10.2337/diacare.24.8.1433 · DOI
  55. Bowers, 1993, The natural history of patients with claudication with toe pressures of 40 mmHg or less, J Vasc Surg, 18, 506, 10.1016/0741-5214(93)90269-R · DOI
  56. Resnick, 2004, Incidence of lower-extremity amputation in American Indians: the Strong Heart Study, Diabetes Care, 27, 1885, 10.2337/diacare.27.8.1885 · DOI
  57. Tahrani, 2011, Management of type 2 diabetes: new and future developments in treatment, Lancet, 378, 182, 10.1016/S0140-6736(11)60207-9 · DOI
  58. Dluhy, 2008, Intensive glycemic control in the ACCORD and ADVANCE trials, N Engl J Med, 358, 2630, 10.1056/NEJMe0804182 · DOI
  59. 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
  60. 1995, Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial, Am J Cardiol, 75, 894, 10.1016/S0002-9149(99)80683-3 · DOI
  61. Nathan, 2005, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med, 353, 2643, 10.1056/NEJMoa052187 · DOI · Paper page
  62. 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  63. Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470 · DOI · Paper page
  64. 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  65. Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 · DOI · Paper page
  66. Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 · DOI · Paper page
  67. Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
  68. Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
  69. Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431 · DOI · Paper page
  70. Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987 · DOI · Paper page
  71. 2003, Peripheral arterial disease in people with diabetes, Diabetes Care, 26, 3333, 10.2337/diacare.26.12.3333 · DOI · Paper page
  72. 2003, Standards of medical care for patients with diabetes mellitus, Diabetes Care, S33
  73. Skyler, 2009, J Am Coll Cardiol, 53, 298, 10.1016/j.jacc.2008.10.008 · DOI
  74. Welch, 1998, Homocysteine and atherothrombosis, N Engl J Med, 338, 1042, 10.1056/NEJM199804093381507 · DOI · Paper page
  75. van den Bosch, 2003, Hyperhomocysteinemia and risk for peripheral arterial occlusive disease in young women, J Vasc Surg, 38, 772, 10.1016/S0741-5214(03)00476-2 · DOI
  76. Malinow, 1989, Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease, Circulation, 79, 1180, 10.1161/01.CIR.79.6.1180 · DOI
  77. Darius, 2003, Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients, Eur J Clin Invest, 33, 751, 10.1046/j.1365-2362.2003.01196.x · DOI
  78. Taylor, 1991, The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease, J Vasc Surg, 13, 128, 10.1016/0741-5214(91)90020-U · DOI
  79. den Heijer, 1996, Hyperhomocysteinemia as a risk factor for deep-vein thrombosis, N Engl J Med, 334, 759, 10.1056/NEJM199603213341203 · DOI
  80. Vermeulen, 2000, Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial, Lancet, 355, 517, 10.1016/S0140-6736(99)07391-2 · DOI
  81. Lonn, 2006, Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial, Can J Cardiol, 22, 47, 10.1016/S0828-282X(06)70238-0 · DOI
  82. Armitage, 2010, Effects of homocysteine-lowering with folic acid plus vitamin B12 vs. placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial, JAMA, 303, 2486, 10.1001/jama.2010.840 · DOI · Paper page
  83. Antithrombotic Trialists Collaboration, 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71 · DOI · Paper page
  84. 1994, Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, BMJ, 308, 81, 10.1136/bmj.308.6921.81 · DOI
  85. Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1 · DOI · Paper page
  86. 1994, Collaborative overview of randomised trials of antiplatelet therapy–II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration, BMJ, 308, 159, 10.1136/bmj.308.6922.159 · DOI
  87. Balsano, 1993, Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group, Circulation, 87, 1563, 10.1161/01.CIR.87.5.1563 · DOI
  88. Berger, 2009, Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials, JAMA, 301, 1909, 10.1001/jama.2009.623 · DOI
  89. Catalano, 2007, Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial, J Intern Med, 261, 276, 10.1111/j.1365-2796.2006.01763.x · DOI · Paper page
  90. 1996, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee, Lancet, 348, 1329, 10.1016/S0140-6736(96)09457-3 · DOI · Paper page
  91. Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746 · DOI · Paper page
  92. Bhatt, 2006, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N Engl J Med, 354, 1706, 10.1056/NEJMoa060989 · DOI
  93. Cacoub, 2009, Patients with peripheral arterial disease in the CHARISMA trial, Eur Heart J, 30, 192, 10.1093/eurheartj/ehn534 · DOI
  94. Belch, 2010, Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial, J Vasc Surg, 52, 825, 10.1016/j.jvs.2010.04.027 · DOI
  95. Cosmi, 2001, Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication, Cochrane Database Syst Rev, 10.1002/14651858.CD001999 · DOI
  96. 2000, Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial, Lancet, 355, 346, 10.1016/S0140-6736(99)07199-8 · DOI
  97. Sobel, 2008, Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition), Chest, 133, 815S, 10.1378/chest.08-0686 · DOI
  98. O'Brien-Irr, 2010, Endovascular intervention for treatment of claudication: is it cost-effective?, Ann Vasc Surg, 24, 833, 10.1016/j.avsg.2010.03.025 · DOI
  99. Treesak, 2004, Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease, Vasc Med, 9, 279, 10.1191/1358863x04vm570oa · DOI
  100. Gardner, 1995, Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis, JAMA, 274, 975, 10.1001/jama.1995.03530120067043 · DOI · Paper page
  101. Leng, 2000, Exercise for intermittent claudication, Cochrane Database Syst Rev, 10.1002/14651858.CD000990 · DOI
  102. McDermott, 2009, Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial, JAMA, 301, 165, 10.1001/jama.2008.962 · DOI · Paper page
  103. Murphy, 2012, CLEVER Study Investigators: Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study, Circulation, 125, 130, 10.1161/CIRCULATIONAHA.111.075770 · DOI
  104. Regensteiner, 1997, Hospital vs. home-based exercise rehabilitation for patients with peripheral arterial occlusive disease, Angiology, 48, 291, 10.1177/000331979704800402 · DOI
  105. Degischer, 2002, Physical training for intermittent claudication: a comparison of structured rehabilitation versus home-based training, Vasc Med, 7, 109, 10.1191/1358863x02vm432oa · DOI
  106. Gardner, 2011, Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial, Circulation, 123, 491, 10.1161/CIRCULATIONAHA.110.963066 · DOI · Paper page
  107. Stewart, 2002, Exercise training for claudication, N Engl J Med, 347, 1941, 10.1056/NEJMra021135 · DOI
  108. Duscha, 2011, Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients, Arterioscler Thromb Vasc Biol, 31, 2742, 10.1161/ATVBAHA.111.230441 · DOI
  109. Lloyd, 2001, Arteriogenesis and angiogenesis in rat ischemic hindlimb: role of nitric oxide, Am J Physiol Heart Circ Physiol, 281, H2528, 10.1152/ajpheart.2001.281.6.H2528 · DOI
  110. Mathien, 1990, Muscle blood flow in trained rats with peripheral arterial insufficiency, Am J Physiol, 258, H759
  111. Laufs, 2004, Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis, Circulation, 109, 220, 10.1161/01.CIR.0000109141.48980.37 · DOI
  112. Prior, 2004, What makes vessels grow with exercise training?, J Appl Physiol, 97, 1119, 10.1152/japplphysiol.00035.2004 · DOI
  113. Niebauer, 1999, Impaired aerobic capacity in hypercholesterolemic mice: partial reversal by exercise training, Am J Physiol, 276, H1346
  114. Buckwalter, 2003, Endogenous vascular remodeling in ischemic skeletal muscle: a role for nitric oxide, J Appl Physiol, 94, 935, 10.1152/japplphysiol.00378.2002 · DOI
  115. Gardner, 2001, Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial, J Am Geriatr Soc, 49, 755, 10.1046/j.1532-5415.2001.49152.x · DOI
  116. Hiatt, 1990, Benefit of exercise conditioning for patients with peripheral arterial disease, Circulation, 81, 602, 10.1161/01.CIR.81.2.602 · DOI
  117. Gokce, 2002, Effect of exercise on upper and lower extremity endothelial function in patients with coronary artery disease, Am J Cardiol, 90, 124, 10.1016/S0002-9149(02)02433-5 · DOI
  118. Brendle, 2001, Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease, Am J Cardiol, 87, 324, 10.1016/S0002-9149(00)01367-9 · DOI
  119. Brass, 1996, Skeletal muscle metabolism as a target for drug therapy in peripheral arterial disease, Vasc Med, 1, 55, 10.1177/1358863X9600100110 · DOI
  120. Hiatt, 1996, Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease, J Appl Physiol, 81, 780, 10.1152/jappl.1996.81.2.780 · DOI
  121. Gardner, 2001, Altered gait profile in subjects with peripheral arterial disease, Vasc Med, 6, 31, 10.1177/1358836X0100600106 · DOI
  122. Villemur, 2011, New rehabilitation program for intermittent claudication: interval training with active recovery. Pilot study, Ann Phys Rehabil Med, 54, 275, 10.1016/j.rehab.2011.05.003 · DOI
  123. Bronas, 2011, Comparison of the effect of upper body-ergometry aerobic training vs. treadmill training on central cardiorespiratory improvement and walking distance in patients with claudication, J Vasc Surg, 53, 1557, 10.1016/j.jvs.2011.01.077 · DOI
  124. Saxton, 2011, Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease, J Vasc Surg, 53, 1265, 10.1016/j.jvs.2010.10.125 · DOI
  125. Oida, 2003, Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers, J Atheroscler Thromb, 10, 93, 10.5551/jat.10.93 · DOI
  126. Tanaka, 1988, Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle, Pharmacology, 36, 313, 10.1159/000138400 · DOI
  127. Woo, 2002, Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans, Clin Pharmacol Ther, 71, 246, 10.1067/mcp.2002.122474 · DOI
  128. Igawa, 1990, Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells, Thromb Res, 57, 617, 10.1016/0049-3848(90)90079-R · DOI
  129. Pande, 2010, A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication, Vasc Med, 15, 181, 10.1177/1358863X10361545 · DOI
  130. Soga, 2011, Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia, J Vasc Surg, 54, 1659, 10.1016/j.jvs.2011.06.024 · DOI
  131. Miyashita, 2011, Cilostazol increases skin perfusion pressure in severely ischemic limbs, Angiology, 62, 15, 10.1177/0003319710371619 · DOI
  132. Dawson, 2000, A comparison of cilostazol and pentoxifylline for treating intermittent claudication, Am J Med, 109, 523, 10.1016/S0002-9343(00)00569-6 · DOI
  133. Cohn, 1998, A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators, N Engl J Med, 339, 1810, 10.1056/NEJM199812173392503 · DOI
  134. Packer, 1991, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group, N Engl J Med, 325, 1468, 10.1056/NEJM199111213252103 · DOI
  135. Hiatt, 2008, Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects), J Vasc Surg, 47, 330, 10.1016/j.jvs.2007.10.009 · DOI
  136. Reiter, 2004, Prostanoids for intermittent claudication, Cochrane Database Syst Rev
  137. Mohler, 2003, Hiatt WR, Olin JW, et al: Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial, J Am Coll Cardiol, 41, 1679, 10.1016/S0735-1097(03)00299-7 · DOI
  138. Lievre, 2000, Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group, Circulation, 102, 426, 10.1161/01.CIR.102.4.426 · DOI
  139. Creager, 2008, A randomized trial of iloprost in patients with intermittent claudication, Vasc Med, 13, 5, 10.1177/1358863X07084910 · DOI
  140. 1991, Second European Consensus Document on chronic critical leg ischemia, Circulation, 84, IV1
  141. 1999, Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori, Ann Intern Med, 130, 412, 10.7326/0003-4819-130-5-199903020-00005 · DOI
  142. 2000, Two randomised and placebo-controlled studies of an oral prostacyclin analogue (iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group, Eur J Vasc Endovasc Surg, 20, 358, 10.1053/ejvs.2000.1175 · DOI
  143. Belch, 2011, The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia, Int Angiol, 30, 150
  144. Lewis, 1989, Nifedipine in patients with peripheral vascular disease, Eur J Vasc Surg, 3, 159, 10.1016/S0950-821X(89)80012-X · DOI
  145. Bagger, 1997, Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment, Circulation, 95, 411, 10.1161/01.CIR.95.2.411 · DOI
  146. Dawson, 2002, Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication, Angiology, 53, 509, 10.1177/000331970205300503 · DOI
  147. Schratzberger, 1999, Mediator-dependent effects of pentoxifylline on endothelium for transmigration of neutrophils, Immunopharmacology, 41, 65, 10.1016/S0162-3109(98)00052-6 · DOI
  148. Rao, 1990, Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication, J Lab Clin Med, 115, 738
  149. Hood, 1996, Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials, CMAJ, 155, 1053
  150. Girolami, 1999, Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis, Arch Intern Med, 159, 337, 10.1001/archinte.159.4.337 · DOI
  151. 1995, Intravenous pentoxifylline for the treatment of chronic critical limb ischaemia. The European Study Group, Eur J Vasc Endovasc Surg, 9, 426, 10.1016/S1078-5884(05)80011-5 · DOI
  152. 1996, Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. A placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group, Int Angiol, 15, 75
  153. Broderick, 1992, Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart, J Biol Chem, 267, 3758, 10.1016/S0021-9258(19)50590-7 · DOI
  154. Hiatt, 2001, Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication, Am J Med, 110, 616, 10.1016/S0002-9343(01)00704-5 · DOI
  155. Brevetti, 1999, European multicenter study on propionyl-l-carnitine in intermittent claudication, J Am Coll Cardiol, 34, 1618, 10.1016/S0735-1097(99)00373-3 · DOI
  156. Brevetti, 1995, Propionyl-l-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study, J Am Coll Cardiol, 26, 1411, 10.1016/0735-1097(95)00344-4 · DOI
  157. Brevetti, 1997, Effect of propionyl-l-carnitine on quality of life in intermittent claudication, Am J Cardiol, 79, 777, 10.1016/S0002-9149(96)00867-3 · DOI
  158. Hiatt, 2011, Effect of propionyl-l-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease, J Cardiopulm Rehabil Prev, 31, 125, 10.1097/HCR.0b013e3181f1fd65 · DOI
  159. Stanley, 2004, Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies, J Cardiovasc Pharmacol Ther, 9, S31, 10.1177/107424840400900104 · DOI
  160. Ma, 2006, A pilot study of ranolazine in patients with intermittent claudication, Int Angiol, 25, 361
  161. Chaitman, 2004, v: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina, J Am Coll Cardiol, 43, 1375, 10.1016/j.jacc.2003.11.045 · DOI
  162. Chaitman, 2004, Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial, JAMA, 291, 309, 10.1001/jama.291.3.309 · DOI
  163. Isner, 1999, Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization, J Clin Invest, 103, 1231, 10.1172/JCI6889 · DOI
  164. Vincent, 2000, Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor, Circulation, 102, 2255, 10.1161/01.CIR.102.18.2255 · DOI
  165. Takeshita, 1994, Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model, J Clin Invest, 93, 662, 10.1172/JCI117018 · DOI
  166. Yang, 1996, Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation, Circ Res, 79, 62, 10.1161/01.RES.79.1.62 · DOI
  167. Tsurumi, 1996, Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion, Circulation, 94, 3281, 10.1161/01.CIR.94.12.3281 · DOI
  168. Isner, 1998, Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results, J Vasc Surg, 28, 964, 10.1016/S0741-5214(98)70022-9 · DOI
  169. Baumgartner, 1998, Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia, Circulation, 97, 1114, 10.1161/01.CIR.97.12.1114 · DOI
  170. Rajagopalan, 2003, Circulation, 108, 1933, 10.1161/01.CIR.0000093398.16124.29 · DOI
  171. Lederman, 2002, Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial, Lancet, 359, 2053, 10.1016/S0140-6736(02)08937-7 · DOI
  172. Comerota, 2002, Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial, J Vasc Surg, 35, 930, 10.1067/mva.2002.123677 · DOI
  173. Nikol, 2008, Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia, Mol Ther, 16, 972, 10.1038/mt.2008.33 · DOI
  174. Belch, 2011, Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia, Lancet, 377, 1929, 10.1016/S0140-6736(11)60394-2 · DOI
  175. Powell, 2008, Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia, Circulation, 118, 58, 10.1161/CIRCULATIONAHA.107.727347 · DOI
  176. Wang, 1995, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc Natl Acad Sci U S A, 92, 5510, 10.1073/pnas.92.12.5510 · DOI · Paper page
  177. Guillemin, 1997, The hypoxic response: huffing and HIFing, Cell, 89, 9, 10.1016/S0092-8674(00)80176-2 · DOI
  178. Wenger, 1997, Oxygen(es) and the hypoxia-inducible factor-1, Biol Chem, 378, 609
  179. Rajagopalan, 2007, Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience, Circulation, 115, 1234, 10.1161/CIRCULATIONAHA.106.607994 · DOI
  180. Creager, 2011, Effect of hypoxia-inducible factor-1{alpha} gene therapy on walking performance in patients with intermittent claudication, Circulation, 124, 1765, 10.1161/CIRCULATIONAHA.110.009407 · DOI
  181. Kalka, 2000, Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization, Proc Natl Acad Sci U S A, 97, 3422, 10.1073/pnas.97.7.3422 · DOI
  182. Kamihata, 2001, Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines, Circulation, 104, 1046, 10.1161/hc3501.093817 · DOI
  183. Shintani, 2001, Augmentation of postnatal neovascularization with autologous bone marrow transplantation, Circulation, 103, 897, 10.1161/01.CIR.103.6.897 · DOI
  184. Tateishi-Yuyama, 2002, Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial, Lancet, 360, 427, 10.1016/S0140-6736(02)09670-8 · DOI
  185. Forbes, 2010, Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. Commentary, J Vasc Surg, 51, 1568, 10.1016/j.jvs.2010.02.019 · DOI
  186. Walter, 2011, Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA), Circ Cardiovasc Interv, 4, 26, 10.1161/CIRCINTERVENTIONS.110.958348 · DOI
  187. Wester, 2008, Treatment with autologous bone marrow mononuclear cells in patients with critical lower limb ischaemia. A pilot study, Scand J Surg, 97, 56, 10.1177/145749690809700108 · DOI
  188. Lara-Hernandez, 2010, Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia, Ann Vasc Surg, 24, 287, 10.1016/j.avsg.2009.10.012 · DOI
  189. Lu, 2011, Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial, Diabetes Res Clin Pract, 92, 26, 10.1016/j.diabres.2010.12.010 · DOI
  190. Perin, 2011, A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia, Catheter Cardiovasc Interv, 78, 1060, 10.1002/ccd.23066 · DOI
  191. Powell, 2011, Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia, J Vasc Surg, 54, 1032, 10.1016/j.jvs.2011.04.006 · DOI
  192. Sprengers, 2010, Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia, J Vasc Surg, 51, 1564, 10.1016/j.jvs.2010.02.020 · DOI
  193. Mohler, 2003, Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease, Circulation, 108, 1481, 10.1161/01.CIR.0000090686.57897.F5 · DOI
  194. Aronow, 2003, Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment, Am J Cardiol, 92, 711, 10.1016/S0002-9149(03)00833-6 · DOI
  195. Mondillo, 2003, Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease, Am J Med, 114, 359, 10.1016/S0002-9343(03)00010-X · DOI
  196. Hiatt, 2010, Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease, Vasc Med, 15, 171, 10.1177/1358863X09360579 · DOI
  197. Brown, 1993, Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease, Circulation, 87, 1781, 10.1161/01.CIR.87.6.1781 · DOI
  198. Liao, 1991, Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis, Circ Res, 68, 1027, 10.1161/01.RES.68.4.1027 · DOI
  199. Anderson, 1995, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, N Engl J Med, 332, 488, 10.1056/NEJM199502233320802 · DOI
  200. Treasure, 1995, Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease, N Engl J Med, 332, 481, 10.1056/NEJM199502233320801 · DOI

200 of 224 shown

Cited by

Sorted by citations

See all 12

Metadata

Authors
Gornik, H. L., & Creager, M. A.
Affiliations
Harvard University (US)
ORCID
Venue
Vascular Medicine: A Companion to Braunwald's Heart Disease
Publisher
Elsevier
Published
2013
Pages
242-258
DOI
10.1016/b978-1-4377-2930-6.00019-7
OpenAlex
W2555551390
Cited by
12
References
10
Citations by year
2023: 1 · 2021: 5 · 2020: 1 · 2019: 2 · 2017: 2
FWCI
2.34
Type
book chapter
Language
en
Open access
closed
Locations
Elsevier eBooks (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vascular Procedures and Complications
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords
peripheral arterial disease, medical therapy, antiplatelet therapy, anticoagulation, lipid-lowering therapy, vasodilator therapy, revascularization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review